文献速递临床试验与 GCP

CT引导下蓝染与对比剂标记胸膜下肺结节后行VATS楔形切除的BLUEPAT前瞻性随机研究

Labelling of subpleural pulmonary nodules with blue dye and contrast agents under CT-guided control and subsequent video-assisted thoracoscopic resection: the BLUEPAT prospective randomised study.
PubMed 文献 · Trials · 2026-04-28

BLUEPAT为前瞻性单中心开放标签随机试验,计划纳入72例需组织学诊断的胸膜下肺结节患者,按1:1随机分为Patent Blue V联合碘海醇CT引导标记后VATS楔形切除组与直接VATS切除对照组,评估可行性、安全性及不良事件,随访30天,本文报告试验方案。

要点

  • 胸膜下小肺结节CT引导下Patent Blue V联合碘海醇标记后行VATS楔形切除。
  • 随机1:1对照,计划样本72例,主要评估可行性与安全性。
  • 所有入组患者随访30天并记录相关不良事件。

核心结论

  • BLUEPAT试验旨在评估CT引导下Patent Blue V联合碘海醇标记胸膜下肺结节后行VATS楔形切除的可行性与安全性。
  • 本文为试验方案报告,结局数据将在研究完成后发表。

研究设计与样本

  • 前瞻性、单中心、开放标签、随机对照试验,计划纳入72例需额外组织学诊断的胸膜下肺结节患者。
  • 患者按1:1随机分为标记后VATS楔形切除组与直接VATS切除对照组。
  • 所有入组患者接受30天随访,记录相关不良事件。

关键数值与推荐

  • 干预组在CT引导下以Patent Blue V和对比剂碘海醇标记肺结节后行VATS楔形切除。
  • 对照组不先行颜色标记直接行VATS切除。
  • 可行性及安全性依据主要和次要目标参数评估,安全性通过记录所有相关不良事件监测。

临床怎么用

  • 该方案拟将颜色标记技术引入并优化至局灶性肺疾病诊治的常规管理。
  • Patent Blue V在乳腺癌诊断程序中已成熟应用,本研究将其扩展至肺部适应症。

局限性

  • 本文仅报告试验方案,尚无结局数据。
  • 单中心设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colour marking of indicated nodules is an innovative, accurate, and gentle method that allows subsequent wedge resection of the marked tissue using a mini-invasive, video-assisted thoracoscopic (VATS) method with all its benefits. One of the expected benefits of this clinical trial is introducing and optimising the evaluated way into routine management in diagnosing and treating focal lung diseases. The BLUEPAT clinical trial aims to assess the technique of colour marking of subpleural deposited small lung nodules with the subsequent performance of VATS wedge resection in surgical practice. METHODS: The BLUEPAT clinical trial is a prospective, monocentric, open-label, randomised study that will include 72 participants with subpleural deposited nodules with the need for additional histological diagnostics to optimise subsequent treatment. These patients will be randomised into two arms in a 1:1 ratio. The interventional arm will undergo VATS wedge resection of lung nodules marked with Patent Blue V and contrast agent iohexol under CT-guided control. The control arm will undergo VATS resection without prior colour coding of the lung nodules. The feasibility and safety of both methods will be assessed based on the evaluation of the parameters of the primary and secondary objectives of the study. The safety of the methods will be monitored by recording all related adverse events. All enrolled patients will undergo a 30-day follow-up period within the framework of clinical trial. RESULTS: This article reports the clinical trial protocol; outcome data will be published upon study completion. DISCUSSION: The BLUEPAT clinical trial offers a novel assessment of this innovative approach for the diagnosis and treatment of focal lung diseases. The use of patent blue dye has been well established in diagnostic procedures for breast cancer and this study extends its potential application to pulmonary indications. TRIAL REGISTRATION: EudraCT Number 2021-001122-22. Registered on March 18, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chovanec Z, Červeňák V, Čundrle I, et al. Labelling of subpleural pulmonary nodules with blue dye and contrast agents under CT-guided control and subsequent video-assisted thoracoscopic resection: the BLUEPAT prospective randomised study. Trials. 2026. PMID: 42045970. doi:10.1186/s13063-026-09748-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。